Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Debt to Equity (2016)

Gyre Therapeutics (GYRE) has disclosed Debt to Equity for 7 consecutive years, with $0.0 as the latest value for Q3 2016.

  • Quarterly Debt to Equity fell 92.35% to $0.0 in Q3 2016 from the year-ago period, while the trailing twelve-month figure was $0.0 through Sep 2016, down 92.35% year-over-year, with the annual reading at $0.04 for FY2015, N/A changed from the prior year.
  • Debt to Equity for Q3 2016 was $0.0 at Gyre Therapeutics, down from $0.01 in the prior quarter.
  • The five-year high for Debt to Equity was $0.04 in Q4 2015, with the low at -$0.02 in Q4 2012.
  • Average Debt to Equity over 5 years is $0.01, with a median of $0.01 recorded in 2013.
  • The sharpest move saw Debt to Equity tumbled 214.97% in 2012, then soared 341.03% in 2015.
  • Over 5 years, Debt to Equity stood at -$0.02 in 2012, then soared by 143.25% to $0.01 in 2013, then plummeted by 54.02% to $0.0 in 2014, then soared by 768.93% to $0.04 in 2015, then crashed by 96.12% to $0.0 in 2016.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.0, $0.01, and $0.01 for Q3 2016, Q2 2016, and Q1 2016 respectively.